查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1930052

全球糖尿病足潰瘍治療市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考察以及未來預測（2025-2034）

Diabetic Foot Ulcer Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 請詢問到貨日

價格

糖尿病足潰瘍治療市場成長因素

2025年全球糖尿病足潰瘍（DFU）治療市場規模將達93.6億美元，預計2026年成長至99.2億美元。到2034年，該市場預計將達到163.6億美元，2026年至2034年的年複合成長率（CAGR）為6.44%。北美地區在2025年佔據市場主導地位，市場佔有率達38.88%。這主要歸因於糖尿病足潰瘍的高發病率、人們對早期治療意識的不斷提高以及為引進先進治療方案而開展的合作不斷擴大。

糖尿病足潰瘍是第1型和第2型糖尿病患者常見的併發症，其特徵是足部出現難以癒合的傷口。這些潰瘍可能導致嚴重的感染，嚴重時甚至需要截肢。糖尿病足潰瘍治療市場包括先進的傷口敷料，例如抗菌敷料、水凝膠敷料和泡沫敷料；傷口護理設備，例如負壓傷口治療（NPWT）和高壓氧治療（HBOT）；主動治療，例如皮膚移植替代物；以及輔助產品，例如負重裝置。

市場驅動因素

該市場的成長主要受糖尿病及其相關足潰瘍盛行率上升的驅動。全球每年約有1860萬人受到影響，其中包括美國的160萬人，顯示市場對先進治療方法的需求很高。人口老化、生活方式改變以及肥胖症的流行也導致了糖尿病足潰瘍（DFU）發病率的上升。

技術進步和創新產品的推出也在推動市場成長。例如，Smith+Nephew於2024年4月推出了RENASYS EDGE負壓傷口治療系統，這是一款用於治療慢性傷口的緊湊型家用護理設備。同樣，用於皮膚移植的生長因子等生物活性療法也在促進傷口癒合，縮短恢復時間。

市場限制因子

先進的DFU治療費用高昂，傷口恢復期長，仍是挑戰。嚴重的潰瘍可能需要長達190天才能癒合，這增加了患者和醫療保健系統的經濟負擔。然而，已開發國家的政府償付政策緩解一些經濟壓力，並支持治療產品的推廣應用。

市場趨勢

市場正逐漸從傳統的傷口管理產品轉向先進的產品。先進的傷口護理敷料，包括水膠體敷料、水凝膠敷料和抗菌敷料，透過維持最佳的濕潤環境和控制感染，促進傷口更快癒合。各大公司加大研發投入和推出新產品，更加速了這些敷料的普及。例如，Varco Leg Care 於2023年 12月推出了 "Ulsr Soothe Max" ，目的是有效治療糖尿病足潰瘍和靜脈曲張潰瘍。

依細分市場分析

依潰瘍類型劃分：市場分為神經源性缺血性潰瘍、神經性潰瘍、缺血性潰瘍。由於神經源性缺血性潰瘍的高發生率以及若不及時治療可能導致嚴重併發症，預計到2026年，該細分市場將佔據 58.45%的最大市場佔有率。由於糖尿病患者常伴隨週邊神經病變和周邊動脈疾病，神經性潰瘍和缺血性潰瘍仍將佔據相當大的市場佔有率。

依產品劃分：傷口護理敷料預計到2026年將佔據最大的市場佔有率，達到42.42%，這主要得益於其易用性、有效的滲出液管理和加速癒合。傷口護理器材和主動治療產品預計將穩定成長，其中主動治療產品預計將呈現最高的年複合成長率，這主要歸功於人們對生物活性和先進療法的認知度和接受度不斷提高。

依最終用戶劃分：醫院預計到2026年將佔據最大的市場佔有率，達到39.48%，這反映了患者更傾向於在臨床環境中接受專業護理。由於醫療保健支出增加、償付政策以及創新家庭醫療保健療法（例如2022年獲得中國國家藥品監督管理局批准的局部傷口氧療（TWO2）療法）的出現，診所、門診手術中心和家庭醫療保健機構也經歷成長。

區域展望

北美將引領市場，2025年市場規模將達36.4億美元。預計到2026年，美國市場規模將達到35.6億美元，主要得益於高盛行率、先進的醫療保健基礎設施以及合作措施。歐洲將佔據第二大市場佔有率，預計到2026年，英國和德國的市場規模將分別達到3.4億美元和7億美元。亞太地區預計將實現最高的年複合成長率，這主要得益於人口老化、生活方式的改變以及日本、中國和印度等主要企業的擴張。儘管拉丁美洲和中東及非洲的市場佔有率較小，但由於監管審批的增加和醫療保健支出的擴大，預計這些地區的市場將實現成長。

本報告詳細概述了糖尿病足潰瘍（DFU）治療市場。報告涵蓋市場驅動因素、限制因素、趨勢、按潰瘍類型、產品類型和最終用戶劃分的市場細分、區域分析和競爭格局，以及對醫療保健支出、盛行率和監管審批的深入分析。報告也聚焦在新冠疫情的影響以及疫情後市場的復甦情況。

市場成長的主要驅動因素是糖尿病及相關足部潰瘍發病率的上升、老年人口的成長、生活方式的改變以及先進傷口護理產品的日益普及。負壓傷口治療（NPWT）系統、水凝膠和抗菌敷料以及生物活性療法等技術進步改善治療效果、提高患者依從性並縮短復原時間。

從傳統傷口管理向先進傷口管理的轉變，以及家庭護理療法（例如局部傷口氧療（TWO2）系統）的日益普及，擴大市場覆蓋範圍。雖然高昂的治療費用和較長的癒合時間帶來了挑戰，但已開發地區的償付政策和不斷成長的醫療保健支出緩解這些限制。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 2025年各國糖尿病足潰瘍（DFU）盛行率
  • 2025年各國糖尿病足潰瘍（DFU）治療費用
  • 2025年各國傷口護理經濟負擔
  • 主要公司新產品發布
  • 關鍵產業趨勢：併購（併購），合作
  • COVID-19 對全球糖尿病足潰瘍治療市場的影響

第5章 全球糖尿病足潰瘍治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依潰瘍類型劃分
    • 神經性潰瘍
    • 缺血性潰瘍
    • 神經缺血性潰瘍
  • 市場分析、洞察與預測：依產品劃分
    • 傷口護理敷料
      • 抗菌敷料
      • 泡棉敷料
      • 薄膜敷料
      • 藻酸鹽敷料
      • 水凝膠敷料
      • 其他敷料
    • 傷口護理設備
      • 負壓傷口護理非週邊傷口治療（NPWT）
      • 超音波療法
      • 高壓氧療法（HBOT）
      • 其他
    • 主動療法
      • 皮膚移植與替代療法
      • 生長因子
      • 其他
    • 其他
  • 市場分析、洞察與預測：依最終用戶劃分
    • 醫院
    • 診所
    • 門診手術中心
    • 家庭醫療保健
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美糖尿病足潰瘍治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲糖尿病足潰瘍治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第8章 亞太地區糖尿病足潰瘍治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲糖尿病足潰瘍治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

    第10章 中東與非洲糖尿病足潰瘍治療市場分析：洞察與預測（2021-2034）

    • 依國家劃分
      • GCC
      • 南非
      • 其他地區中東和非洲地區

    第11章 競爭分析

    • 全球市場佔有率分析（2025年）
    • 公司簡介
    • Coloplast A/S
    • Smith+Nephew
    • 3M
    • Convatec Inc.
    • Integra LifeSciences
    • B. Braun SE
    • Cardinal Health
    • Molnlycke Health Care AB
    • Essity Aktiebolag（publ）.
Product Code: FBI101948

Growth Factors of diabetic foot ulcer (DFU) treatment Market

The global diabetic foot ulcer (DFU) treatment market was valued at USD 9.36 billion in 2025 and is expected to grow to USD 9.92 billion in 2026. By 2034, the market is projected to reach USD 16.36 billion, registering a CAGR of 6.44% from 2026 to 2034. North America dominated the market in 2025 with a 38.88% share, fueled by the high prevalence of diabetic foot ulcers, rising awareness for early treatment, and growing collaborations to launch advanced treatment solutions.

Diabetic foot ulcers are common complications in patients with type 1 and type 2 diabetes, characterized by non-healing wounds typically on the feet. These ulcers can lead to severe infections and, in extreme cases, amputation. The DFU treatment market includes advanced wound dressings such as antimicrobials, hydrogel, and foam dressings, wound-care devices including negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBOT), active therapies like skin graft substitutes, and supportive products such as offloading devices.

Market Drivers

The market is primarily driven by the rising prevalence of diabetes and related foot ulcers. Globally, about 18.6 million people are affected annually, including 1.6 million in the U.S., highlighting the significant demand for advanced treatment options. The growing geriatric population, lifestyle changes, and obesity further contribute to the increasing incidence of DFUs.

Technological advancements and the introduction of innovative products also drive market growth. For instance, Smith+Nephew launched the RENASYS EDGE NPWT system in April 2024, a compact, homecare-friendly device for chronic wound treatment. Similarly, bioactive therapies such as skin grafting growth factors are enhancing wound healing and reducing recovery times.

Market Restraints

The high cost of advanced DFU treatments and the longer duration of wound recovery remain challenges. Severe ulcers can take up to 190 days to heal, increasing the economic burden on patients and healthcare systems. However, government reimbursement policies in developed countries mitigate some financial constraints, supporting the adoption of treatment products.

Market Trends

There is a shift from traditional to advanced wound management products. Advanced wound care dressings, including hydrocolloids, hydrogels, and antimicrobial dressings, promote faster healing by maintaining optimal moisture balance and controlling infections. Increasing R&D initiatives and product launches by key players further accelerate adoption. For example, Varco Leg Care launched Ulsr Soothe Max in December 2023, designed to treat DFUs and varicose vein ulcers efficiently.

Segmentation Analysis

By Ulcer Type: The market is segmented into neuro-ischemic, neuropathic, and ischemic ulcers. The neuro-ischemic segment dominated in 2026 with a 58.45% share, due to its prevalence and risk of severe complications if untreated. Neuropathic and ischemic ulcers also hold significant shares, driven by peripheral neuropathy and peripheral artery disease among diabetic patients.

By Product: Wound-care dressings accounted for the largest share in 2026 at 42.42%, due to ease of use, effective exudate management, and faster healing. Wound-care devices and active therapies are expected to grow steadily, with active therapies showing the highest CAGR due to increased awareness and adoption of bioactive and advanced treatment options.

By End-user: Hospitals held the largest share of 39.48% in 2026, reflecting patient preference for skilled care in clinical settings. Clinics, ambulatory surgical centers, and home care settings are also witnessing growth due to rising healthcare expenditure, reimbursement policies, and innovative homecare therapies such as Topical Wound Oxygen (TWO2) therapy approved by China's NMPA in 2022.

Regional Insights

North America led with a market size of USD 3.64 billion in 2025, with the U.S. projected to reach USD 3.56 billion by 2026, supported by high prevalence, advanced healthcare infrastructure, and collaborative initiatives. Europe held the second-largest share, with the U.K. and Germany projected to reach USD 0.34 billion and USD 0.7 billion respectively by 2026. Asia Pacific is expected to register the highest CAGR, driven by a rising geriatric population, lifestyle changes, and expansion by key players in Japan, China, and India. Latin America and the Middle East & Africa hold smaller shares but are expected to grow due to increased regulatory approvals and healthcare expenditure.

Competitive Landscape

The market is highly fragmented, with key players such as 3M, Smith+Nephew, Molnlycke Health Care AB, Cardinal Health, B. Braun SE, Convatec Inc., and Integra LifeSciences focusing on product innovation, strategic collaborations, acquisitions, and expanding global footprints. Recent developments include 3M FDA approvals in 2023 for advanced Veraflo Therapy dressings and Convatec's acquisition of Triad Life Sciences in 2022 to strengthen their biologics portfolio.

Report Coverage

The report provides a detailed overview of the DFU treatment market, including market drivers, restraints, trends, segmentation by ulcer type, product, and end-user, regional analysis, and competitive landscape, along with insights on healthcare expenditure, prevalence, and regulatory approvals. It also highlights the impact of COVID-19 and the recovery of the market post-pandemic.

Conclusion

The global diabetic foot ulcer treatment market, valued at USD 9.36 billion in 2025, is projected to grow to USD 9.92 billion in 2026 and reach USD 16.36 billion by 2034, reflecting a CAGR of 6.44% from 2026 to 2034. North America continues to lead the market, supported by the high prevalence of DFUs, advanced healthcare infrastructure, growing awareness for early intervention, and collaborative initiatives to launch innovative treatment solutions.

Market growth is primarily driven by the rising incidence of diabetes and associated foot ulcers, the expanding geriatric population, lifestyle changes, and increasing adoption of advanced wound care products. Technological advancements, including NPWT systems, hydrogel and antimicrobial dressings, and bioactive therapies, have enhanced treatment effectiveness, improved patient compliance, and shortened recovery times.

The shift from traditional to advanced wound management and the growing adoption of homecare-based therapies, such as Topical Wound Oxygen (TWO2) systems, are expanding market accessibility. While the high cost of treatment and longer healing durations pose challenges, reimbursement policies and increasing healthcare expenditure in developed regions mitigate these constraints.

Segmentation By Ulcer Type

  • Neuropathic Ulcer
  • Ischemic Ulcers
  • Neuro-ischemic Ulcer

By Product

  • Wound-care Dressings
    • Antimicrobial Dressings
    • Foam Dressings
    • Film Dressings
    • Alginate Dressings
    • Hydrogel Dressings
    • Other Dressings
  • Wound-care Devices
    • Negative Pressure Wound Therapy (NPWT)
    • Ultrasound Therapy
    • Hyperbaric Oxygen Therapy (HBOT)
    • Others
  • Active Therapies
    • Skin Grafts & Substitutes
    • Growth Factors
    • Others
  • Others

By End User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Homecare Settings

By Region

  • North America (By Ulcer Type, By Product, By End User, and By Country)
    • U.S.
    • Canada
  • Europe (By Ulcer Type, By Product, By End User, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Ulcer Type, By Product, By End User, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Ulcer Type, By Product, By End User, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa ( By Ulcer Type, By Product, By End User, and By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Number of Diabetic Foot Ulcer (DFU) Patients, By Key Countries, 2025
  • 4.2. Cost of Diabetic Foot Ulcer (DFU) Treatment, By Key Countries, 2025
  • 4.3. Economic Cost Burden, Wound Care, By Key Countries, 2025/2025
  • 4.4. New Product Launches, By Key Players
  • 4.5. Key Industry Developments: Mergers, Acquisitions, Partnerships
  • 4.6. Impact of COVID-19 on the Global Diabetic Foot Ulcer Treatment Market

5. Global Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Ulcer Type
    • 5.1.1. Neuropathic Ulcer
    • 5.1.2. Ischemic Ulcers
    • 5.1.3. Neuro-Ischemic Ulcer
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. Wound-care Dressings
      • 5.2.1.1. Antimicrobial Dressings
      • 5.2.1.2. Foam Dressings
      • 5.2.1.3. Film Dressings
      • 5.2.1.4. Alginate Dressings
      • 5.2.1.5. Hydrogel Dressings
      • 5.2.1.6. Other Dressings
    • 5.2.2. Wound-care Devices
      • 5.2.2.1. Negative Pressure Wound Therapy (NPWT)
      • 5.2.2.2. Ultrasound Therapy
      • 5.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
      • 5.2.2.4. Others
    • 5.2.3. Active Therapies
      • 5.2.3.1. Skin Grafts & Substitutes
      • 5.2.3.2. Growth Factors
      • 5.2.3.3. Others
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals
    • 5.3.2. Clinics
    • 5.3.3. Ambulatory Surgical Centers
    • 5.3.4. Homecare Settings
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Ulcer Type
    • 6.1.1. Neuropathic Ulcer
    • 6.1.2. Ischemic Ulcers
    • 6.1.3. Neuro-Ischemic Ulcer
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. Wound-care Dressings
      • 6.2.1.1. Antimicrobial Dressings
      • 6.2.1.2. Foam Dressings
      • 6.2.1.3. Film Dressings
      • 6.2.1.4. Alginate Dressings
      • 6.2.1.5. Hydrogel Dressings
      • 6.2.1.6. Other Dressings
    • 6.2.2. Wound-care Devices
      • 6.2.2.1. Negative Pressure Wound Therapy (NPWT)
      • 6.2.2.2. Ultrasound Therapy
      • 6.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
      • 6.2.2.4. Others
    • 6.2.3. Active Therapies
      • 6.2.3.1. Skin Grafts & Substitutes
      • 6.2.3.2. Growth Factors
      • 6.2.3.3. Others
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals
    • 6.3.2. Clinics
    • 6.3.3. Ambulatory Surgical Centers
    • 6.3.4. Homecare Settings
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Ulcer Type
    • 7.1.1. Neuropathic Ulcer
    • 7.1.2. Ischemic Ulcers
    • 7.1.3. Neuro-Ischemic Ulcer
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. Wound-care Dressings
      • 7.2.1.1. Antimicrobial Dressings
      • 7.2.1.2. Foam Dressings
      • 7.2.1.3. Film Dressings
      • 7.2.1.4. Alginate Dressings
      • 7.2.1.5. Hydrogel Dressings
      • 7.2.1.6. Other Dressings
    • 7.2.2. Wound-care Devices
      • 7.2.2.1. Negative Pressure Wound Therapy (NPWT)
      • 7.2.2.2. Ultrasound Therapy
      • 7.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
      • 7.2.2.4. Others
    • 7.2.3. Active Therapies
      • 7.2.3.1. Skin Grafts & Substitutes
      • 7.2.3.2. Growth Factors
      • 7.2.3.3. Others
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Ambulatory Surgical Centers
    • 7.3.4. Homecare Settings
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. Germany
    • 7.4.2. U.K.
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Ulcer Type
    • 8.1.1. Neuropathic Ulcer
    • 8.1.2. Ischemic Ulcers
    • 8.1.3. Neuro-Ischemic Ulcer
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. Wound-care Dressings
      • 8.2.1.1. Antimicrobial Dressings
      • 8.2.1.2. Foam Dressings
      • 8.2.1.3. Film Dressings
      • 8.2.1.4. Alginate Dressings
      • 8.2.1.5. Hydrogel Dressings
      • 8.2.1.6. Other Dressings
    • 8.2.2. Wound-care Devices
      • 8.2.2.1. Negative Pressure Wound Therapy (NPWT)
      • 8.2.2.2. Ultrasound Therapy
      • 8.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
      • 8.2.2.4. Others
    • 8.2.3. Active Therapies
      • 8.2.3.1. Skin Grafts & Substitutes
      • 8.2.3.2. Growth Factors
      • 8.2.3.3. Others
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Ambulatory Surgical Centers
    • 8.3.4. Homecare Settings
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Ulcer Type
    • 9.1.1. Neuropathic Ulcer
    • 9.1.2. Ischemic Ulcers
    • 9.1.3. Neuro-Ischemic Ulcer
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. Wound-care Dressings
      • 9.2.1.1. Antimicrobial Dressings
      • 9.2.1.2. Foam Dressings
      • 9.2.1.3. Film Dressings
      • 9.2.1.4. Alginate Dressings
      • 9.2.1.5. Hydrogel Dressings
      • 9.2.1.6. Other Dressings
    • 9.2.2. Wound-care Devices
      • 9.2.2.1. Negative Pressure Wound Therapy (NPWT)
      • 9.2.2.2. Ultrasound Therapy
      • 9.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
      • 9.2.2.4. Others
    • 9.2.3. Active Therapies
      • 9.2.3.1. Skin Grafts & Substitutes
      • 9.2.3.2. Growth Factors
      • 9.2.3.3. Others
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Ambulatory Surgical Centers
    • 9.3.4. Homecare Settings
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Diabetic Foot Ulcer Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Ulcer Type
    • 10.1.1. Neuropathic Ulcer
    • 10.1.2. Ischemic Ulcers
    • 10.1.3. Neuro-Ischemic Ulcer
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. Wound-care Dressings
      • 10.2.1.1. Antimicrobial Dressings
      • 10.2.1.2. Foam Dressings
      • 10.2.1.3. Film Dressings
      • 10.2.1.4. Alginate Dressings
      • 10.2.1.5. Hydrogel Dressings
      • 10.2.1.6. Other Dressings
    • 10.2.2. Wound-care Devices
      • 10.2.2.1. Negative Pressure Wound Therapy (NPWT)
      • 10.2.2.2. Ultrasound Therapy
      • 10.2.2.3. Hyperbaric Oxygen Therapy (HBOT)
      • 10.2.2.4. Others
    • 10.2.3. Active Therapies
      • 10.2.3.1. Skin Grafts & Substitutes
      • 10.2.3.2. Growth Factors
      • 10.2.3.3. Others
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals
    • 10.3.2. Clinics
    • 10.3.3. Ambulatory Surgical Centers
    • 10.3.4. Homecare Settings
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Coloplast A/S
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Smith+Nephew
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. 3M
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Convatec Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Integra LifeSciences
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. B. Braun SE
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Cardinal Health
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Molnlycke Health Care AB
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Essity Aktiebolag (publ).
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Ulcer Type, 2021-2034
  • Table 2: Global Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 3: Global Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Dressings, 2021-2034
  • Table 4: Global Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Devices, 2021-2034
  • Table 5: Global Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Active Therapies, 2021-2034
  • Table 6: Global Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 7: Global Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Ulcer Type, 2021-2034
  • Table 9: North America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 10: North America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Dressings, 2021-2034
  • Table 11: North America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Devices, 2021-2034
  • Table 12: North America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Active Therapies, 2021-2034
  • Table 13: North America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 14: North America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 15: Europe Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Ulcer Type, 2021-2034
  • Table 16: Europe Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 17: Europe Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Dressings, 2021-2034
  • Table 18: Europe Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Devices, 2021-2034
  • Table 19: Europe Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Active Therapies, 2021-2034
  • Table 20: Europe Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 21: Europe Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Ulcer Type, 2021-2034
  • Table 23: Asia Pacific Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 24: Asia Pacific Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Dressings, 2021-2034
  • Table 25: Asia Pacific Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Devices, 2021-2034
  • Table 26: Asia Pacific Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Active Therapies, 2021-2034
  • Table 27: Asia Pacific Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 28: Asia Pacific Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: Latin America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Ulcer Type, 2021-2034
  • Table 30: Latin America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 31: Latin America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Dressings, 2021-2034
  • Table 32: Latin America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Devices, 2021-2034
  • Table 33: Latin America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Active Therapies, 2021-2034
  • Table 34: Latin America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 35: Latin America Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Ulcer Type, 2021-2034
  • Table 37: Middle East & Africa Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 38: Middle East & Africa Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Dressings, 2021-2034
  • Table 39: Middle East & Africa Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Wound-care Devices, 2021-2034
  • Table 40: Middle East & Africa Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by Active Therapies, 2021-2034
  • Table 41: Middle East & Africa Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 42: Middle East & Africa Diabetic Foot Ulcer Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Diabetic Foot Ulcer Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Diabetic Foot Ulcer Treatment Market Value Share (%), by Ulcer Type, 2025 & 2034
  • Figure 3: Global Diabetic Foot Ulcer Treatment Market Value Share (%), by Product, 2025 & 2034
  • Figure 4: Global Diabetic Foot Ulcer Treatment Market Value Share (%), by End User, 2025 & 2034
  • Figure 5: Global Diabetic Foot Ulcer Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 6: North America Diabetic Foot Ulcer Treatment Market Value (USD billion), by Ulcer Type, 2025 & 2034
  • Figure 7: North America Diabetic Foot Ulcer Treatment Market Value Share (%), by Ulcer Type, 2025
  • Figure 8: North America Diabetic Foot Ulcer Treatment Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America Diabetic Foot Ulcer Treatment Market Value Share (%), by Product, 2025
  • Figure 10: North America Diabetic Foot Ulcer Treatment Market Value (USD billion), by End User, 2025 & 2034
  • Figure 11: North America Diabetic Foot Ulcer Treatment Market Value Share (%), by End User, 2025
  • Figure 12: North America Diabetic Foot Ulcer Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Diabetic Foot Ulcer Treatment Market Value Share (%), By Country, 2025
  • Figure 14: Europe Diabetic Foot Ulcer Treatment Market Value (USD billion), by Ulcer Type, 2025 & 2034
  • Figure 15: Europe Diabetic Foot Ulcer Treatment Market Value Share (%), by Ulcer Type, 2025
  • Figure 16: Europe Diabetic Foot Ulcer Treatment Market Value (USD billion), by Product, 2025 & 2034
  • Figure 17: Europe Diabetic Foot Ulcer Treatment Market Value Share (%), by Product, 2025
  • Figure 18: Europe Diabetic Foot Ulcer Treatment Market Value (USD billion), by End User, 2025 & 2034
  • Figure 19: Europe Diabetic Foot Ulcer Treatment Market Value Share (%), by End User, 2025
  • Figure 20: Europe Diabetic Foot Ulcer Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Diabetic Foot Ulcer Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Diabetic Foot Ulcer Treatment Market Value (USD billion), by Ulcer Type, 2025 & 2034
  • Figure 23: Asia Pacific Diabetic Foot Ulcer Treatment Market Value Share (%), by Ulcer Type, 2025
  • Figure 24: Asia Pacific Diabetic Foot Ulcer Treatment Market Value (USD billion), by Product, 2025 & 2034
  • Figure 25: Asia Pacific Diabetic Foot Ulcer Treatment Market Value Share (%), by Product, 2025
  • Figure 26: Asia Pacific Diabetic Foot Ulcer Treatment Market Value (USD billion), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Diabetic Foot Ulcer Treatment Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Diabetic Foot Ulcer Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Diabetic Foot Ulcer Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Diabetic Foot Ulcer Treatment Market Value (USD billion), by Ulcer Type, 2025 & 2034
  • Figure 31: Latin America Diabetic Foot Ulcer Treatment Market Value Share (%), by Ulcer Type, 2025
  • Figure 32: Latin America Diabetic Foot Ulcer Treatment Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Latin America Diabetic Foot Ulcer Treatment Market Value Share (%), by Product, 2025
  • Figure 34: Latin America Diabetic Foot Ulcer Treatment Market Value (USD billion), by End User, 2025 & 2034
  • Figure 35: Latin America Diabetic Foot Ulcer Treatment Market Value Share (%), by End User, 2025
  • Figure 36: Latin America Diabetic Foot Ulcer Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Diabetic Foot Ulcer Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Diabetic Foot Ulcer Treatment Market Value (USD billion), by Ulcer Type, 2025 & 2034
  • Figure 39: Middle East & Africa Diabetic Foot Ulcer Treatment Market Value Share (%), by Ulcer Type, 2025
  • Figure 40: Middle East & Africa Diabetic Foot Ulcer Treatment Market Value (USD billion), by Product, 2025 & 2034
  • Figure 41: Middle East & Africa Diabetic Foot Ulcer Treatment Market Value Share (%), by Product, 2025
  • Figure 42: Middle East & Africa Diabetic Foot Ulcer Treatment Market Value (USD billion), by End User, 2025 & 2034
  • Figure 43: Middle East & Africa Diabetic Foot Ulcer Treatment Market Value Share (%), by End User, 2025
  • Figure 44: Middle East & Africa Diabetic Foot Ulcer Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Diabetic Foot Ulcer Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Diabetic Foot Ulcer Treatment Market Share (%), By Company, 2025